October 16, 2018

Bringing cutting-edge imaging techniques to clinical trials

Dr. Catherine Coolens with new DCE-CT calibration device

OICR offers new CT calibration service as part of its Collaborative Research Resources portfolio

 Using imaging devices to help make treatment decisions in the clinic requires rigorous testing, quality assurance and routine calibration of the imaging machinery. These standards are especially important when the imaging technology is novel or unique, such as in the case of perfusion imaging – a relatively new technique used to diagnose a cancer’s stage by showing how blood flows through the tumour.

Continue reading – Bringing cutting-edge imaging techniques to clinical trials

October 16, 2018

Meet the researchers: Kelly McDonald

Kelly McDonald talks about her work at the Ontario Heath Study and how the data provided by participants is now helping researchers in Canada and around the world.

October 11, 2018

FACIT Welcomes Har Grover and Ken Lawless to the Board

Strategic appointments of seasoned entrepreneurs add expertise and strengthen governance

TORONTO, ON (October 11, 2018) — FACIT announced the appointment of two new members to its Board, Mr. Har Grover and Mr. Ken Lawless. Both leaders are passionate supporters of the Ontario life science sector, have broad industry experience and decades of work with entrepreneurial ventures. As FACIT drives oncology innovations to the marketplace and highlights Ontario as a top-tier destination for biotech investment, strong governance by its Board is critical to achieving this mandate.

Continue reading – FACIT Welcomes Har Grover and Ken Lawless to the Board

October 2, 2018

Understanding how cancer differs between sexes

Connie Li

OICR researchers uncover sex-linked genetic differences that may be able to predict cancer severity and response to therapy

Cancer differs in males and females but the origins and mechanisms of these sex differences remain unresolved. A better understanding of sex-linked differences in cancer could lead to more accurate tests and treatments that are personalized for patients based on their sex.

Continue reading – Understanding how cancer differs between sexes

September 25, 2018

Breast cancer radiotherapy in a single visit provides more convenient option to patients, reduces burden of therapy

Seeds used in radiation therapy are shown, along with a penny to provide scale.

Cross-Canada research team moves image-guided ultrasound system into clinical development

Traditional breast cancer radiation treatment requires multiple hospital visits over a period of weeks or months, which may be onerous to patients who live far from hospitals or in remote communities. An alternative radiotherapy technique, Permanent Breast Seed Implantation (PBSI), requires only a single hospital visit, but it involves the implantation of multiple small radioactive metal pellets into the breast of the patient within millimetres of a target. The procedure to administer this treatment is difficult to plan and complex to execute – impeding the adoption of PBSI in the clinic.

Continue reading – Breast cancer radiotherapy in a single visit provides more convenient option to patients, reduces burden of therapy

September 24, 2018

Breaking down barriers to translation: A case of standardization in digital pathology

Jane Bayani In the lab.

OICR takes part in international multicentre study to standardize promising breast cancer digital pathology test

The Ki67 immunohistochemistry assay is a test that can help evaluate the aggressiveness of breast tumours, predict disease outcomes, monitor cancer progression and identify patients who are more likely to respond to a given therapy. Despite its potential to help patients with breast cancer, the analysis of Ki67 has not been widely adopted in the clinic, mostly due to the lack of standardization across laboratories.

Continue reading – Breaking down barriers to translation: A case of standardization in digital pathology

September 20, 2018

Dr. Paul Boutros receives prestigious award from the Canadian Cancer Society

Dr. Paul Boutros

Today, OICR’s Dr. Paul Boutros was named the 2018 winner of the Bernard and Francine Dorval Prize. The award is part of the Canadian Cancer Society’s Awards for Excellence in Cancer Research.

Continue reading – Dr. Paul Boutros receives prestigious award from the Canadian Cancer Society

September 14, 2018

Great Canadian Hair “Do” 2018

Today, a group of OICR staff members and others from the community once again took part in the Great Canadian Hair “Do” in support of The Terry Fox Foundation. Together they raised more than $10,000. Thank you to all who donated and came out to support the team. The team is still accepting online donations.

September 13, 2018

Using imaging to better detect, characterize and monitor prostate cancers

Justin Lau

Sunnybrook researchers develop new magnetic resonance imaging methods to help differentiate between aggressive and non-aggressive prostate cancers

Current needle biopsy techniques have limited accuracy in detecting prostate cancer and determining the tumour’s aggressiveness. New methods are needed to better detect and characterize prostate cancer so that each patient can get the treatment that is most appropriate for them.

Continue reading – Using imaging to better detect, characterize and monitor prostate cancers

September 13, 2018

FACIT invests in three top Ontario entrepreneur-teams from near record pool of applicants

Prospects Oncology Fund seeds developing pipeline of Ontario-based biotech innovations

TORONTO, ON (September 13, 2018) – With an expanding portfolio of breakthrough innovations, FACIT is committed to supporting Ontario entrepreneurs through the latest round of its Prospects Oncology Fund. FACIT has selected three novel cancer therapeutic discoveries to receive early-stage capital – biotechnology start-up Talon Pharmaceuticals (“Talon”), the Drug Discovery team at the Ontario Institute for Cancer Research (“OICR”) and CCRM. The Prospects Fund provides entrepreneurial scientists with the capital resources necessary to achieve critical proof-of-principle studies for their cutting-edge breakthroughs aiming to benefit future patients.

Continue reading – FACIT invests in three top Ontario entrepreneur-teams from near record pool of applicants

September 11, 2018

Portal to access world’s largest database of pediatric genomic data goes live

OICR’s Genome Informatics team plays key role in development of the Gabriella Miller Kids First Data Resource Portal

Toronto (September 11, 2018) – Today, the Gabriella Miller Kids First Data Resource Center (DRC) at the Children’s Hospital of Philadelphia launched the Kids First Data Resource Portal, which will advance personalized medicine for the detection, therapy, and management of childhood cancer and structural birth defects. As the Kids First DRC’s chief outward-facing tool, the Kids First Data Resource Portal serves the needs of a diverse group of patients, researchers, and clinicians partnering to create the world’s largest database of pediatric genomic data, and provides the necessary tools and computational resources for their analysis and interpretation.

Continue reading – Portal to access world’s largest database of pediatric genomic data goes live

September 10, 2018

Researchers find unexpected cells at the centre of recurrent leukemia

Dr. Mick Bhatia poses for a photo in his lab.

Hamilton researchers discover that cancer stem cells may not be the only culprits of acute myeloid leukemia relapse

Although current chemotherapy for acute myeloid leukemia (AML) is effective in the short term, the disease often returns a few years after treatment. A new study suggests that the relapse of leukemia may not be caused by leukemic stem cells – a special set of cells that can avoid initial treatment by not dividing, then give rise to new cancerous cells after therapy – but rather a different class of leukemic cells.

Continue reading – Researchers find unexpected cells at the centre of recurrent leukemia

Next Page »